Скачать с ютуб Diagnosing Alzheimer’s disease using blood-based biomarkers в хорошем качестве

Diagnosing Alzheimer’s disease using blood-based biomarkers

Amyloid beta and tau deposition are widely used biomarkers for Alzheimer’s diagnosis that reflect the underlying disease pathology. Changes in these proteins in cerebral spinal fluid or amyloid-PET can confirm the presence of Alzheimer’s. Charlotte Teunissen, PhD, VU University Medical Center, Amsterdam, The Netherlands, talks on recent technological developments that have enabled the measurement of amyloid and tau in the blood. Strong data supporting the reliability of these serum biomarkers has been published recently, meaning they may represent a rapid, non-invasive, and low-cost tool for Alzheimer’s diagnosis and screening. This interview took place during the European Academy of Neurology 2021 congress.